• Citer

Immunomodulation through the anti-inflammatory cholinergic pathway: impact on innate and acquired immunity in transplantation

par Sadis, Claude
Promoteur Le Moine, Alain
Co-Promoteur Florquin, Sandrine
Publication Non publié, 2015-11-18

Thèse de doctorat

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Up to now, solid organ transplantation remains the ultimate life-saving treatment for end-stage organ failure. However, transplantation could be complicated by allograft rejection wherein inflammation plays a pivotal role. In this process, inflammation secondary to ischemia/reperfusion and cell necrosis plays the role of adjuvant and enhances the antigen-specific adaptive response ultimately leading to allograft rejection. Therefore, anti-inflammatory strategies have to be developed to dampen inflammation and secondary alloreactivity. Recently, neuroimmune pathways and particularly the cholinergic anti-inflammatory pathway have been described to modulate inflammation in several experimental models as sepsis. The Vagus Nerve, the α7 nicotinic receptor (α7nAChR) and its agonists are specific targets to regulate the inflammatory response in several pathologies.The aim of this work is to investigate the potential protective effect of the cholinergic pathway in solid organ transplantation. In a model of renal ischemia/reperfusion injury induced by bilateral clamping of renal arteries, nicotine protects from renal dysfunction and tubular damages. This protection is associated to a reduction of inflammatory cytokines and neutrophils and is α7nAChR dependent. In a second part, we test the effect of the α7nACh receptor in a model of minor antigen mismatched skin allograft. Mice deficient for the α7nAChR reject earlier the skin allograft compared to α7nAChR +/+ mice and this is associated to higher Th1 and Th17 T cell responses. α7nAChR expressed on T cells is involved in skin allograft rejection as attested by adoptive transfer experiments in Rag H/H mice with either α7nAChR +/+ or α7nAChR H/H alloreactive T cells. The cholinergic pathway by itself or boosted by nicotinic agonists is able to modulate innate as well as acquired immune components involved in allograft rejection. Other agonists or devices used to stimulate the cholinergic pathway are actually developed in order to be more specific and to reduce toxicity. Our results are particularly relevant in human medicine as grafted organs lose their Vagus Nerve endings and their cholinergic regulatory innervation.